Funding boost gets Sunho Biologics over the IPO filing line
The cash-burning biotech has applied to list on the Hong Kong Stock Exchange after only barely achieving the minimum market value Key Takeaways: With no product or licensing revenue, Sunho…
Recent Articles
RELATED ARTICLES
-
InSilico seeks IPO boost to get AI drugs over the line
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
HBM gets health boost from drug licensing deals
2142.HK
-
Kintor shares plunge after hair-loss drug flops in clinical trials
9939.HK
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
- HighTide Therapeutics places big IPO bet on “affluenza” drug
-
With no cure in sight, drugs firm LianBio begins exit strategy
LIAN.US
